These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34648139)

  • 1. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
    Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
    Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
    Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
    Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.
    Yang Y; Li F; Du L
    J Nanobiotechnology; 2024 May; 22(1):304. PubMed ID: 38822339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
    Tang Q; Owens RJ; Naismith JH
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
    Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
    EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
    Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
    Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
    Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization.
    Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X
    J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of
    Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
    Elife; 2021 Aug; 10():. PubMed ID: 34338634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants.
    He L; Wu Q; Zhang Z; Chen L; Yu K; Li L; Jia Q; Wang Y; Ni J; Wang C; Li Q; Zhai X; Zhao J; Liu Y; Fan R; Li YP
    Mol Pharm; 2024 Aug; 21(8):3866-3879. PubMed ID: 38920116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
    Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
    Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
    Cornish K; Huo J; Jones L; Sharma P; Thrush JW; Abdelkarim S; Kipar A; Ramadurai S; Weckener M; Mikolajek H; Liu S; Buckle I; Bentley E; Kirby A; Han X; Laidlaw SM; Hill M; Eyssen L; Norman C; Le Bas A; Clarke J; James W; Stewart JP; Carroll M; Naismith JH; Owens RJ
    Open Biol; 2024 Jun; 14(6):230252. PubMed ID: 38835241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
    Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
    J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.